Contract wins build momentum at life sciences group
York-based life sciences business, Aptamer Group, says its sales for H1 2022 increased to £1.37 m (H1 2021: £485,000).
The company, which floated on the AIM market in December, has published a trading update for the six months ended 31 December 2021 and will release its interim results on 31 March 2022.
Aptamer aims to solve problems for biotech and big pharma by developing molecular binders called aptamers, as an alternative to antibodies which fail to perform 50% to 60% of the time.
The business says that during the period covered by its trading update, it added to its partner portfolio with new agreements across all its units.
Contracts were signed with WuXi AppTec Research Services Division and ProAxsis. Apatamer also signed deals with a top five pharmaceutical company for bioanalytical reagents to support vaccine development, and with a public life science company to support proteomic analysis.
Following the period end, Aptamer signed a new contract with a precision oncology company for companion diagnostic development.
Arron Tolley, chief executive officer, said: “Following Aptamer’s successful IPO on AIM in December, the Group has a robust financial base that will enable it to capitalise on the extensive next-generation affinity ligand market opportunity.
“In addition, the Group will scale up and automate our Optimer® platform to increase internal capacity and develop aptamers to support a larger customer base in H2 2022 and beyond.
“The second half of the year has started well, and the Group continues to build momentum across the business with new agreements in each of the business units.”
